Federal Cannabis Descheduling Legislation: Bills, Timeline & Impact

Executive Summary

Federal descheduling legislation represents the most comprehensive approach to ending cannabis prohibition at the national level by removing marijuana entirely from the Controlled Substances Act (CSA) rather than merely reclassifying it to a lower schedule. Unlike rescheduling proposals that would move cannabis from Schedule I to Schedule III under the CSA framework established by 21 U.S.C. § 812, descheduling bills seek to eliminate federal criminal penalties altogether and treat cannabis similarly to alcohol or tobacco. The reintroduction of descheduling legislation in July 2026 marks the latest chapter in a decades-long effort to align federal law with state-level reforms, where 38 states have legalized medical cannabis and 24 have approved adult-use programs. Descheduling would resolve the fundamental conflict between state-legal cannabis businesses and federal prohibition, eliminate IRS Code Section 280E tax penalties that prevent standard business deductions, enable interstate commerce, and allow federally chartered banks to serve the industry without fear of money laundering prosecution. The legislative path remains challenging despite growing public support exceeding 70% in national polls, requiring passage through both chambers of Congress and presidential signature while navigating opposition from law enforcement groups, pharmaceutical interests, and social conservative organizations.

Why Federal Descheduling Matters

Complete removal of cannabis from the Controlled Substances Act would fundamentally transform a $33 billion legal industry currently operating in legal limbo between state authorization and federal prohibition. The stakes extend far beyond the cannabis industry itself. Approximately 500,000 Americans work directly in state-legal cannabis businesses, from cultivation facilities in California to dispensaries in Massachusetts, all technically violating federal law under 21 U.S.C. § 841 despite state licenses. These businesses collectively paid an estimated $1.8 billion in additional federal taxes in 2025 due to Section 280E, which prohibits standard business expense deductions for operations trafficking in Schedule I or II substances. Medical cannabis patients represent another critical stakeholder group. Over 7 million registered patients across 38 medical programs rely on cannabis for conditions ranging from chronic pain to epilepsy, yet face potential federal prosecution, loss of federal employment, housing discrimination in federally subsidized properties, and firearm ownership restrictions under 18 U.S.C. § 922(g)(3). Veterans receiving care through the Department of Veterans Affairs cannot receive cannabis recommendations from VA physicians despite high rates of PTSD and chronic pain in veteran populations. The financial sector remains largely closed to cannabis businesses due to federal prohibition. Fewer than 800 of the nation's 4,800 federally insured banks actively serve cannabis clients, according to FinCEN reporting, forcing most dispensaries and cultivators to operate on a cash basis. This creates public safety risks, complicates tax collection, and prevents normal business operations including payroll processing, merchant services, and commercial lending. State governments have collected over $15 billion in cannabis tax revenue since Colorado launched adult-use sales in 2014, funding education, infrastructure, and drug treatment programs. However, interstate commerce remains prohibited, forcing each state to maintain entirely separate supply chains even when neighboring states have legalized. Descheduling would enable efficient regional markets and reduce the price disparities that currently range from $200 per ounce in Oregon to over $400 in Illinois.

Historical Background and Legislative Evolution

The path to federal descheduling began with cannabis prohibition in 1937 and has accelerated dramatically since California legalized medical use in 1996, creating an increasingly untenable conflict between state and federal law.

The Marihuana Tax Act and Early Prohibition (1937-1970)

Federal cannabis prohibition originated with the Marihuana Tax Act of 1937, which imposed prohibitive taxes and registration requirements on cannabis transactions. The Act effectively criminalized cannabis possession and transfer while maintaining a veneer of taxation authority. This framework remained in place until the Supreme Court struck it down in Leary v. United States (1969), ruling that the registration requirement violated Fifth Amendment protections against self-incrimination.

The Controlled Substances Act (1970)

Congress responded by passing the Controlled Substances Act as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970. The CSA established five schedules of controlled substances based on medical utility, abuse potential, and safety profile. Cannabis was temporarily placed in Schedule I pending a report from the Shafer Commission, which President Nixon appointed to study marijuana policy. The Shafer Commission delivered its report in 1972, recommending decriminalization of personal possession and use. Nixon rejected the findings, and cannabis remained in Schedule I alongside heroin and LSD, defined as substances with high abuse potential, no accepted medical use, and lack of accepted safety for use under medical supervision.

State Medical Marijuana Movement (1996-2012)

California voters approved Proposition 215 in 1996, establishing the nation's first medical cannabis program despite federal prohibition. The Clinton, Bush, and Obama administrations struggled with enforcement policy as more states followed. The Supreme Court ruled in Gonzales v. Raich (2005) that Congress could prohibit intrastate cannabis cultivation and possession under the Commerce Clause even in states with medical programs, but federal resources proved insufficient for comprehensive enforcement. By 2012, 18 states had enacted medical cannabis laws. The Obama administration issued the Ogden Memo (2009) and Cole Memo (2013), establishing prosecutorial discretion policies that deprioritized enforcement against state-compliant operators. These guidance documents created operational space for state programs while maintaining federal prohibition.

Adult-Use Legalization Era (2012-Present)

Colorado and Washington voters approved adult-use legalization in November 2012, with retail sales beginning in 2014. This marked a qualitative shift from medical exceptions to full legalization models. Oregon, Alaska, and the District of Columbia followed in 2014. California, Massachusetts, Nevada, and Maine legalized in 2016. By 2026, 24 states had approved adult-use programs serving over 120 million residents.

Federal Legislative Attempts (2019-2026)

The first comprehensive descheduling bill, the Marijuana Opportunity Reinvestment and Expungement (MORE) Act, was introduced in 2019 by Representative Jerrold Nadler. The House passed the MORE Act in December 2020 by a vote of 228-164, marking the first time either chamber approved ending federal cannabis prohibition. The bill died in the Republican-controlled Senate without a vote. The House passed the MORE Act again in April 2022 by 220-204, with only three Republicans supporting and two Democrats opposing. Senate Majority Leader Chuck Schumer introduced the Cannabis Administration and Opportunity Act (CAOA) in July 2022, but the bill never advanced to a floor vote before Republicans regained House control in the 2022 midterms. The 2024 election cycle brought renewed momentum as both major party platforms included cannabis reform language for the first time. The Biden administration initiated a rescheduling process in 2022, with the Department of Health and Human Services recommending Schedule III placement in August 2023. The Drug Enforcement Administration published a Notice of Proposed Rulemaking in May 2024, but the process remained pending as of mid-2026.

2026 Reintroduction

The July 2026 reintroduction of federal descheduling legislation came as the DEA rescheduling process stalled amid administrative law judge hearings and public comment periods. Sponsors argued that rescheduling to Schedule III would resolve some issues, particularly Section 280E tax treatment, but would leave cannabis under CSA restrictions including FDA approval requirements for medical use, DEA manufacturing quotas, and continued federal criminalization of state-legal activities. Descheduling represents a clean break from the CSA framework entirely.

Key Players and Stakeholders

Congressional Sponsors and Champions

Representative Jerrold Nadler of New York has led House descheduling efforts since introducing the MORE Act in 2019. As former House Judiciary Committee chairman, Nadler positioned cannabis reform as a civil rights and criminal justice issue, emphasizing the disproportionate impact of prohibition on Black and Latino communities despite similar usage rates across racial groups. Senator Chuck Schumer of New York has championed Senate efforts, introducing the CAOA and using his position as Majority Leader to prioritize cannabis legislation. Representative Earl Blumenauer of Oregon founded the Congressional Cannabis Caucus in 2017 and has introduced numerous cannabis reform bills. Senator Cory Booker of New Jersey has insisted that federal legalization must include social equity provisions, expungement mechanisms, and community reinvestment programs. Representative Nancy Mace of South Carolina has led Republican reform efforts, introducing the States Reform Act as a conservative alternative emphasizing state rights and limited federal regulation.

Drug Enforcement Administration

The DEA maintains operational authority over controlled substance scheduling under 21 U.S.C. § 811. Administrator Anne Milgram has overseen the ongoing rescheduling review while maintaining that the agency follows scientific evidence and statutory criteria. The DEA has historically opposed removing cannabis from Schedule I, arguing in previous petition denials that insufficient evidence supports accepted medical use under the five-part test established in Alliance for Cannabis Therapeutics v. DEA (1994).

Department of Health and Human Services

HHS, through the Food and Drug Administration, conducts scientific and medical evaluations for scheduling decisions. The August 2023 HHS recommendation to reschedule cannabis to Schedule III marked a significant shift in the federal government's scientific position, concluding that cannabis has accepted medical use and lower abuse potential than Schedule I or II substances. FDA Commissioner Robert Califf has emphasized that rescheduling would not change FDA's drug approval authority and that cannabis products would still require approval for medical claims.

Cannabis Industry Organizations

The National Cannabis Industry Association represents over 1,500 cannabis businesses and has lobbied extensively for descheduling. NCIA argues that Schedule III rescheduling provides insufficient relief because cannabis would remain under CSA restrictions incompatible with state regulatory models. The U.S. Cannabis Council, representing multi-state operators including Curaleaf, Trulieve, and Green Thumb Industries, has focused lobbying efforts on Section 280E relief and banking access. The National Cannabis Roundtable, chaired by former Speaker John Boehner, represents major MSOs and has advocated for incremental reforms including the SAFE Banking Act. Some advocates criticize large operators for prioritizing tax relief over comprehensive reform including expungement and social equity provisions.

Medical and Public Health Organizations

The American Medical Association has called for cannabis to be removed from Schedule I to facilitate research, though it has not endorsed full descheduling. The American Academy of Pediatrics opposes legalization due to concerns about adolescent use and developing brains. The American Public Health Association supports decriminalization and evidence-based regulation. Veterans organizations including the American Legion and Iraq and Afghanistan Veterans of America have strongly supported medical cannabis access and federal reform. The Veterans Cannabis Project advocates specifically for VA physician recommendation authority and research into cannabis for PTSD and traumatic brain injury.

Law Enforcement and Opposition Groups

The National Sheriffs' Association and Major County Sheriffs of America oppose descheduling, arguing that legalization increases impaired driving, youth access, and diversion to illegal markets. Smart Approaches to Marijuana, founded by former Representative Patrick Kennedy, opposes legalization while supporting decriminalization, arguing that commercial cannabis industries prioritize profit over public health. The Community Anti-Drug Coalitions of America receives federal funding for prevention programs and has opposed legalization. Some critics note that law enforcement opposition coincides with financial interests in asset forfeiture revenue and federal grant programs tied to drug enforcement.

Legal and Regulatory Framework

Federal descheduling would require amending the Controlled Substances Act to remove cannabis from Schedule I, fundamentally altering the legal status of marijuana under federal law while leaving states free to maintain their own prohibition or regulatory frameworks.

Current Controlled Substances Act Structure

The CSA establishes five schedules under 21 U.S.C. § 812, with placement determined by eight factors including abuse potential, scientific evidence of pharmacological effect, current scientific knowledge, history and pattern of abuse, scope and significance of abuse, and risk to public health. Schedule I substances must have high abuse potential, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. Cannabis currently appears in Schedule I alongside heroin, LSD, and MDMA. This classification makes cannabis possession a federal crime under 21 U.S.C. § 844, with penalties up to one year imprisonment and $1,000 fine for first offense. Manufacturing and distribution violations under 21 U.S.C. § 841 carry mandatory minimum sentences ranging from five years to life imprisonment depending on quantity.

Descheduling Mechanisms

Congress can deschedule cannabis through legislation, which would amend the CSA to remove marijuana from the schedule lists. This represents the most direct and comprehensive approach, requiring passage through both chambers and presidential signature or veto override. Alternatively, the Attorney General can initiate rescheduling or descheduling through administrative procedures under 21 U.S.C. § 811(a), though this authority has never been used to completely remove a substance from CSA control. The MORE Act and similar descheduling bills would strike cannabis from Schedule I and add provisions preventing federal agencies from denying benefits, security clearances, or immigration status based solely on state-legal cannabis use or employment. The bills typically include expungement provisions directing federal courts to seal or expunge prior cannabis convictions.

Regulatory Authority Post-Descheduling

Descheduling legislation must address which federal agencies would regulate cannabis commerce. Most proposals assign primary authority to the Bureau of Alcohol, Tobacco, Firearms and Explosives, renaming it to include cannabis. ATF would enforce federal excise taxes, licensing requirements, and interstate commerce regulations similar to its current alcohol jurisdiction. The FDA would retain authority over cannabis products making medical or therapeutic claims under the Federal Food, Drug, and Cosmetic Act. The agency could establish good manufacturing practices, testing standards, and labeling requirements. The USDA would likely regulate hemp and cannabis agriculture under existing authorities. The Federal Trade Commission would enforce advertising standards and consumer protection rules. The Occupational Safety and Health Administration would establish workplace safety standards for cultivation and processing facilities.

Tax Structure

Descheduling bills typically impose federal excise taxes on cannabis products, with rates varying by proposal. The MORE Act included a 5% federal sales tax escalating to 8% over three years, with revenue directed to a Community Reinvestment Grant Program, an Equitable Licensing Grant Program, and substance abuse treatment programs. The CAOA proposed a tiered tax structure based on THC content, starting at 10% and increasing to 25% over five years. Critically, descheduling would eliminate Section 280E of the Internal Revenue Code, which currently prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. This provision, originally intended for criminal enterprises, forces state-legal cannabis businesses to pay effective federal tax rates of 70% or higher by disallowing deductions for rent, employee salaries, marketing, and other standard expenses. Descheduling would allow normal tax treatment and dramatically improve cannabis business profitability.

Banking and Financial Services

Federal prohibition creates severe banking challenges under the Bank Secrecy Act and anti-money laundering statutes. Financial institutions serving cannabis businesses risk prosecution for money laundering under 18 U.S.C. § 1956 and aiding and abetting violations of the CSA. The FinCEN guidance issued in 2014 provided limited safe harbor but did not eliminate legal risk. Descheduling would remove these barriers entirely, allowing cannabis businesses to access checking accounts, credit card processing, commercial loans, and public capital markets without legal risk to financial institutions. The SAFE Banking Act, which has passed the House seven times but never cleared the Senate, would provide similar protections without descheduling, but comprehensive reform advocates argue that half-measures perpetuate uncertainty.

Interstate Commerce

The CSA prohibits interstate transportation of controlled substances except as authorized by DEA registration. State-legal cannabis cannot cross state lines even between two legalized states, forcing each state to maintain complete supply chains from cultivation through retail. This creates inefficiencies and price distortions, with wholesale flower prices ranging from $500 per pound in Oregon to $2,500 in Pennsylvania. Descheduling would enable interstate commerce under the Commerce Clause, allowing efficient regional markets. California cultivators could ship to New York dispensaries. Processors could serve multi-state markets. However, states would retain authority to prohibit imports under the Twenty-first Amendment model used for alcohol, where states can restrict interstate alcohol shipments despite federal legality.

State-by-State Landscape

Federal descheduling would not mandate state-level legalization but would remove federal barriers to state regulatory programs and enable interstate commerce between states choosing to participate.

Adult-Use Legal States

Twenty-four states have legalized adult-use cannabis as of mid-2026. California operates the largest market with over $5 billion in annual sales, though high tax rates and regulatory costs have sustained a substantial illicit market. Colorado has collected over $2 billion in tax revenue since 2014, funding school construction and drug treatment programs. Illinois generated $1.4 billion in sales in 2025, with social equity licenses reserved for applicants from communities disproportionately impacted by prohibition. Washington maintains a state-licensed private market with approximately 500 retail locations. Oregon oversupply has driven wholesale prices below production costs for many cultivators. Michigan has rapidly expanded to over 1,000 retail licenses since launching adult-use sales in 2019. Massachusetts requires community host agreements between municipalities and cannabis businesses, creating localized approval processes. Nevada ties its cannabis market to tourism, with dispensaries concentrated in Las Vegas and Reno. Arizona voters approved legalization in 2020 after rejecting a 2016 ballot measure. Montana, New Jersey, New York, Virginia, New Mexico, Connecticut, Rhode Island, Maryland, and Missouri have all launched or are implementing adult-use programs approved between 2020 and 2022.

Medical-Only States

Fourteen states maintain medical cannabis programs without adult-use legalization. Florida operates one of the nation's largest medical programs with over 800,000 registered patients, though a 2024 adult-use ballot measure failed to reach the required 60% threshold. Pennsylvania has over 400,000 medical patients and generates approximately $1.5 billion in annual sales. Ohio voters approved adult-use legalization in 2023, with sales beginning in 2024. Oklahoma has issued over 9,000 cultivation and processing licenses under a medical program with minimal barriers to patient registration. Arkansas, Louisiana, Mississippi, North Dakota, South Dakota, Utah, West Virginia, Alabama, and Kentucky maintain more restrictive medical programs with limited qualifying conditions or product types.

Prohibition States

Twelve states maintain complete cannabis prohibition with no legal medical or adult-use programs: Idaho, Wyoming, Nebraska, Kansas, Wisconsin, Tennessee, South Carolina, Georgia, Indiana, Iowa, Texas, and North Carolina. These states would retain authority to prohibit cannabis possession, cultivation, and sales even after federal descheduling, similar to how some counties remain dry under alcohol law. However, federal descheduling would eliminate federal prosecution risk for individuals in prohibition states, though state charges would remain. Interstate commerce provisions could enable residents of prohibition states to purchase cannabis in neighboring legal states, though transporting it back across state lines might violate state law even if federally legal.

Tribal Sovereignty

Native American tribes possess sovereign authority to regulate cannabis on tribal lands regardless of state law under the 2014 Cole Memo for Indian Country. Over 100 tribes have established cannabis programs, though banking access and interstate commerce restrictions limit market development. Federal descheduling would remove these barriers while respecting tribal sovereignty to prohibit or regulate cannabis independently.

Market and Business Implications

Federal descheduling would unlock an estimated $50-100 billion in additional economic value for the cannabis industry through tax normalization, banking access, interstate commerce, and institutional investment. Multi-state operators would benefit dramatically from Section 280E elimination. Curaleaf, the nation's largest MSO with operations in 18 states, reported $1.3 billion in revenue for 2025 but paid an effective federal tax rate exceeding 70% due to disallowed deductions. Descheduling would immediately improve profitability by 20-30 percentage points, enabling reinvestment in expansion, research and development, and employee compensation. Interstate commerce would enable supply chain consolidation and economies of scale. Cultivation could concentrate in optimal climates like California, Oregon, and Oklahoma where production costs run $200-400 per pound. Processing and manufacturing could centralize in states with favorable business climates. Distribution networks could serve regional markets efficiently rather than duplicating infrastructure in each state. Banking access would reduce operational costs and security risks. Cash-based operations require armored transport, extensive security systems, and cash-counting infrastructure. Credit card processing fees would replace cash handling costs. Commercial lending would enable facility expansion, equipment purchases, and working capital management. Public capital markets would open to cannabis companies currently limited to Canadian exchanges or over-the-counter markets. Institutional investors including pension funds, mutual funds, and insurance companies remain largely excluded from cannabis investments due to federal prohibition. Descheduling would enable major investment firms to allocate capital to the sector, potentially driving a wave of consolidation and professionalization. Analysts project that institutional investment could exceed $20 billion in the first three years following descheduling. Small operators and social equity licensees face different dynamics. Descheduling could accelerate consolidation as large MSOs leverage improved access to capital and economies of scale. Some advocates argue that descheduling legislation must include provisions protecting small businesses, such as limits on vertical integration, caps on license holdings, and preferential access to federal small business programs. Ancillary businesses including software providers, testing laboratories, packaging manufacturers, and compliance consultants would benefit from market expansion and normalization. Real estate values in cannabis-friendly jurisdictions would likely appreciate as federal prohibition risk disappears. Professional services including accounting, legal, and insurance would see increased demand. International implications include potential conflicts with the United Nations Single Convention on Narcotic Drugs, which requires signatories to limit cannabis to medical and scientific purposes. The United States could withdraw from the treaty, seek amendments, or interpret descheduling as consistent with treaty obligations by maintaining FDA drug approval authority for medical claims. Canada and Uruguay have navigated similar issues following their national legalization policies.

What Policy Experts and Stakeholders Say

Policy analysis of federal descheduling reveals sharp divisions between those viewing it as overdue recognition of state-level success and those warning of public health consequences and implementation challenges. The Brookings Institution published analysis in 2025 concluding that federal prohibition has become untenable given state-level legalization covering over 60% of the U.S. population. According to the report, the current framework creates legal uncertainty, prevents effective regulation, and perpetuates racial disparities in enforcement. The analysis recommended descheduling paired with federal regulatory standards for product safety, potency labeling, and marketing restrictions. The RAND Corporation examined cannabis policy options in a 2024 study, finding that descheduling would likely increase cannabis use by 15-30% nationally as prices decline and access expands. The research noted that public health outcomes depend heavily on regulatory design, with strict marketing limits, potency caps, and age verification reducing potential harms. RAND emphasized that descheduling without thoughtful regulation could enable aggressive commercial promotion similar to alcohol and tobacco industries. The Cato Institute has consistently advocated for descheduling from a libertarian perspective, arguing that prohibition violates individual liberty and generates massive enforcement costs without corresponding benefits. According to Cato analysis, the federal government spends approximately $3.6 billion annually on cannabis enforcement, including DEA operations, federal prosecutions, and Bureau of Prisons incarceration costs. These resources could be redirected to treatment, education, and enforcement of regulations protecting minors. The American Civil Liberties Union has prioritized cannabis reform as a criminal justice issue, noting that Black Americans are arrested for cannabis possession at 3.6 times the rate of white Americans despite similar usage rates. ACLU analysis found that over 6 million arrests occurred between 2010 and 2020, with lasting consequences for employment, housing, education, and family stability. The organization argues that descheduling must include automatic expungement of prior convictions and community reinvestment in affected neighborhoods. The National Academy of Sciences published a comprehensive evidence review in 2017 examining cannabis health effects. The report found substantial evidence that cannabis effectively treats chronic pain, chemotherapy-induced nausea, and multiple sclerosis spasticity. It found moderate evidence linking cannabis use to increased motor vehicle accidents, respiratory symptoms from smoking, and triggering schizophrenia in predisposed individuals. The Academy called for removing research barriers to enable more definitive studies. State-level experience provides empirical evidence for policy debates. Colorado's Department of Public Health and Environment has tracked outcomes since 2014, finding that adult use rates increased from 13.6% to 16.8% between 2014 and 2023, while youth use remained stable at approximately 9%. Traffic fatalities involving THC-positive drivers increased, though causation remains difficult to establish given THC's long detection window. Tax revenue exceeded projections, funding school construction and drug treatment programs. Washington State Liquor and Cannabis Board data shows that licensed market prices declined from $25 per gram in 2014 to $6 per gram in 2023, while potency increased from average 15% THC to 22% THC. The state collected $1.8 billion in excise tax revenue through 2025. Illicit market indicators including seizures and arrests declined substantially, suggesting successful market capture.

What Happens Next: Timeline and Scenarios

The path to federal descheduling depends on congressional composition following the 2026 midterm elections, presidential priorities, and whether the DEA rescheduling process concludes before legislative action. The immediate calendar includes several decision points. The DEA administrative law judge hearings on Schedule III rescheduling are scheduled to conclude in September 2026, with a final agency decision expected by early 2027. If the DEA approves rescheduling to Schedule III, some congressional momentum for descheduling could dissipate as the industry gains Section 280E relief and research access improves. However, many advocates argue that Schedule III placement would create new problems. Cannabis would remain under CSA restrictions including DEA manufacturing quotas, FDA approval requirements for medical use, and continued federal criminalization of state-legal activities not meeting pharmaceutical standards. This could create a two-tier system where FDA-approved cannabis medications are legal while state-regulated products remain federally prohibited. The 2026 midterm elections will determine congressional control for the 118th Congress. If Democrats retain or expand Senate control while gaining House seats, descheduling legislation could advance in 2027. If Republicans control both chambers, the path becomes more uncertain, depending on whether the party embraces criminal justice reform and state rights arguments or maintains traditional drug war positions. Presidential leadership remains critical. A president prioritizing cannabis reform could use executive authority to direct agencies to deprioritize enforcement, expand research access, and support legislative efforts. Conversely, an administration opposed to legalization could reverse existing guidance, increase enforcement, and threaten veto of descheduling bills. Incremental reforms could advance before comprehensive descheduling. The SAFE Banking Act has repeatedly passed the House with bipartisan support, though Senate Republicans have blocked floor votes. The bill could pass as a standalone measure or attach to must-pass legislation like defense authorization or appropriations bills. Medical cannabis research bills have attracted bipartisan support and could advance separately. State-level momentum continues regardless of federal action. Several states have adult-use legalization on 2026 ballots, including Florida (second attempt), Nebraska, and South Dakota (third attempt). State legislative sessions in 2027 will consider legalization bills in Pennsylvania, Minnesota, and Wisconsin. Each additional state increases pressure on Congress to resolve the federal-state conflict. International developments may influence U.S. policy. Germany launched adult-use legalization in 2024. Mexico's Supreme Court has ruled prohibition unconstitutional, though implementation remains pending. Thailand legalized and then re-criminalized cannabis in a policy reversal. These international experiments provide additional data on regulatory approaches and outcomes. Litigation could force congressional action. Several lawsuits challenge Schedule I placement on constitutional grounds, arguing that the classification violates due process, equal protection, or federalism principles. While courts have historically deferred to congressional and agency scheduling decisions, the growing state-federal conflict could prompt judicial intervention requiring legislative resolution. Industry consolidation and professionalization increase pressure for federal reform. As MSOs grow larger and more sophisticated, they gain lobbying resources and political influence. Major corporations including alcohol distributors, tobacco companies, and pharmaceutical firms have invested in cannabis companies or developed entry strategies, bringing additional lobbying firepower to reform efforts.

Further Reading and Primary Sources

• Controlled Substances Act, 21 U.S.C. § 801 et seq. — https://www.deadiversion.usdoj.gov/21cfr/21usc/
• Marijuana Opportunity Reinvestment and Expungement (MORE) Act, H.R. 3617 (117th Congress) — https://www.congress.gov/bill/117th-congress/house-bill/3617
• Cannabis Administration and Opportunity Act discussion draft — https://www.democrats.senate.gov/cannabis
• Drug Enforcement Administration, Notice of Proposed Rulemaking on Marijuana Rescheduling (May 2024) — https://www.federalregister.gov/
• Department of Health and Human Services recommendation to reschedule marijuana (August 2023) — https://www.hhs.gov/
• Congressional Research Service, "Marijuana: Medical and Retail—Selected Legal Issues" — https://crsreports.congress.gov/
• National Conference of State Legislatures, State Medical Cannabis Laws — https://www.ncsl.org/health/state-medical-cannabis-laws
• Brookings Institution, "The Cannabis Policy Gap: Understanding Federal and State Conflicts" — https://www.brookings.edu/
• RAND Corporation, "Considering Marijuana Legalization: Insights for Vermont and Other Jurisdictions" — https://www.rand.org/
• National Academies of Sciences, Engineering, and Medicine, "The Health Effects of Cannabis and Cannabinoids" (2017) — https://www.nationalacademies.org/
• American Civil Liberties Union, "A Tale of Two Countries: Racially Targeted Arrests in the Era of Marijuana Reform" — https://www.aclu.org/
• Financial Crimes Enforcement Network, "BSA Expectations Regarding Marijuana-Related Businesses" — https://www.fincen.gov/
• Internal Revenue Service, Tax Code Section 280E — https://www.irs.gov/
• Colorado Department of Public Health and Environment, Marijuana Health Monitoring Data — https://cdphe.colorado.gov/
• Washington State Liquor and Cannabis Board, Cannabis Market Data — https://lcb.wa.gov/